TCP-1 β Antibody (F39 P7 F11): sc-47717
- TCP-1 β Antibody (F39 P7 F11) is a mouse monoclonal IgG2a κ, cited in 3 publications, provided at 200 µg/ml
- raised against ovalbumin-conjugate synthetic peptide RKRVPDHHPC
- recommended for detection of TCP-1β of mouse, rat, human and Xenopus origin by WB, IP, IF and IHC(P)
- m-IgG Fc BP-HRP, m-IgG2a BP-HRP and m-IgGκ BP-HRP are the preferred secondary detection reagents for TCP-1 β Antibody (F39 P7 F11) for WB and IHC(P) applications. These reagents are now offered in bundles with TCP-1 β Antibody (F39 P7 F11) (see ordering information below).
TCP-1 β Antibody (F39 P7 F11) is a mouse monoclonal IgG2a antibody that detects TCP-1 β in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and immunohistochemistry. TCP-1 β is a crucial subunit of the chaperonin containing TCP-1 (CCT) complex, which is essential for the proper folding of cytosolic proteins, particularly actins and tubulins. The CCT complex is composed of eight distinct subunits, each encoded by different genes, and TCP-1 β (F39 P7 F11) antibody helps researchers study these protein interactions. TCP-1 β plays a significant role in ensuring proteins achieve their functional conformations and participates in cellular processes such as cytoskeletal organization and cellular signaling pathways. Abnormalities in TCP-1 β function can lead to various diseases, including neurodegenerative disorders, highlighting its significance in maintaining cellular homeostasis. Anti-TCP-1 β antibody (F39 P7 F11) serves as an invaluable tool for researchers studying the dynamics of protein folding and the implications of chaperonin function in health and disease.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
TCP-1 β Antibody (F39 P7 F11) References:
- Intracellular beta-tubulin/chaperonin containing TCP1-beta complex serves as a novel chemotherapeutic target against drug-resistant tumors. | Lin, YF., et al. 2009. Cancer Res. 69: 6879-88. PMID: 19690144
- CCT2 is an aggrephagy receptor for clearance of solid protein aggregates. | Ma, X., et al. 2022. Cell. 185: 1325-1345.e22. PMID: 35366418
- TSPAN31 regulates the proliferation, migration, and apoptosis of gastric cancer cells through the METTL1/CCT2 pathway. | Ma, X., et al. 2022. Transl Oncol. 20: 101423. PMID: 35429902
- Comprehensive prognostic and immunological analysis of CCT2 in pan-cancer. | Lv, W., et al. 2022. Front Oncol. 12: 986990. PMID: 36119498
- Multi-omics analysis revealed the role of CCT2 in the induction of autophagy in Alzheimer's disease. | Ma, X., et al. 2022. Front Genet. 13: 967730. PMID: 36704351
- PRRSV degrades MDA5 via dual autophagy receptors P62 and CCT2 to evade antiviral innate immunity. | Sun, R., et al. 2024. Virol Sin. 39: 264-276. PMID: 38272236
- Targeting the molecular chaperone CCT2 inhibits GBM progression by influencing KRAS stability. | Zhao, F., et al. 2024. Cancer Lett. 590: 216844. PMID: 38582394
- Trim21-mediated CCT2 ubiquitination suppresses malignant progression and promotes CD4+T cell activation in breast cancer. | Chen, X., et al. 2024. Cell Death Dis. 15: 542. PMID: 39079960
- Two distinct regulatory pathways govern Cct2-Atg8 binding in the process of solid aggrephagy. | Chen, Y., et al. 2024. EMBO Rep. 25: 4749-4776. PMID: 39322741
- The essential role of CCT2 in the regulation of aggrephagy. | Luo, J., et al. 2024. Front Aging Neurosci. 16: 1491001. PMID: 39478698
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
TCP-1 β Antibody (F39 P7 F11) | sc-47717 | 200 µg/ml | $322.00 | |||
TCP-1 β Antibody (F39 P7 F11): m-IgG Fc BP-HRP Bundle | sc-536802 | 200 µg Ab; 10 µg BP | $361.00 | |||
TCP-1 β Antibody (F39 P7 F11): m-IgGκ BP-HRP Bundle | sc-533966 | 200 µg Ab; 40 µg BP | $361.00 | |||
TCP-1 β Antibody (F39 P7 F11): m-IgG2a BP-HRP Bundle | sc-547874 | 200 µg Ab; 10 µg BP | $361.00 |